Participants who initiated long-acting cabotegravir-rilpivirine had a high rate of adherence and virologic suppression, with ...

The investigational oral pre-exposure prophylaxis (PrEP) agent MK-8527 showed a similar, well-tolerated safety profile to ...

The program known as PEPFAR is one of the most effective and popular U.S. foreign aid projects in history, and the government ...

Researchers wanted to provide insight into the relative clinical value of Apretude and lenacapavir compared with no ...

For more than two decades, the global community has united to fight the HIV pandemic, achieving remarkable progress. New HIV transmissions and AIDS-related deaths have dropped significantly, and ...

Experts have proposed new treatment modes for older people with HIV. The new treatment does not cause the health-threatening ...

Let us refresh the old gold Buddhist tale of The Quail and the Net: ldquo;Long ago a flock of quails lived in a forest .

Conference on HIV Science officially opened Monday in the Rwandan capital of Kigali, with a strong call to accelerate access to long-acting HIV prevention and treatment innovations amid growing global ...

WHO recommends twice-yearly injectable lenacapavir for HIV prevention, expanding PrEP options for key populations.

Scientists, researchers, policy makers and HIV/AIDS advocates at a meeting in Kigali, Rwanda, from July 13-17 for the 13th International AIDS Conference on HIV Science (IAS 2025), have raised an alarm ...

Long-acting injectable PrEP may improve access, protection and adherence, especially for young people and pregnant women, according to Hasina Subedar, a senior technical advisor at South Africa’s ...